New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

Semaglutide (known by its brand name Ozempic) has gained widespread attention for its weight-loss benefits, but is officially ...

Scholar Rock aims for a 2025 launch of apitegromab in SMA, expecting $2 billion in global revenue and significant growth from upcoming trials and favorable data.

Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...

Tirzepatide treatment was associated with reduced body weight and diabetes risk across 3 years among individuals with obesity and prediabetes.

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...

Next-gen obesity biotech Metsera has filed to debut on the public markets, proposing an IPO nine months after emerging. | ...